Oragenics, Inc.

Latest News

Oragenics Q2 2025 Shareholder Update

On the Cutting Edge

Oragenics is striving to revolutionize neurological care through proprietary intranasal delivery technology that has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. Our lead candidate, ONP-002, is advancing with the goal of becoming the first FDA-approved treatment for concussion, while our platform technology has the potential, we believe, to open pathways to address neurodegenerative diseases, CNS disorders, and other neurological conditions.

We’re building more than a pharmaceutical company—we’re creating a movement around brain-first recovery that transforms how patients, clinicians, and healthcare systems approach neurological trauma.

Sign up for email updates

Be the first to receive breaking news

Sign Up
NYSE American OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Last Updated: